BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: April-Monn SL, Andreasi V, Schiavo Lena M, Sadowski MC, Kim-Fuchs C, Buri MC, Ketkar A, Maire R, Di Domenico A, Schrader J, Muffatti F, Doglioni C, Partelli S, Falconi M, Perren A, Marinoni I. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers (Basel) 2021;13:5014. [PMID: 34638497 DOI: 10.3390/cancers13195014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Smith J, Barnett E, Rodger EJ, Chatterjee A, Subramaniam RM. Neuroendocrine Neoplasms: Genetics and Epigenetics. PET Clin 2023;18:169-87. [PMID: 36858744 DOI: 10.1016/j.cpet.2022.11.003] [Reference Citation Analysis]
2 April-monn SL, Detjen K, Kirchner P, Bräutigam K, Trippel MA, Marques IJ, Grob T, Statzer C, Maire RS, Kollàr A, Chouchane A, Kunze K, Horst D, Sadowski MC, Schrader J, Mercader N, Marinoni I, Wiedenmann B, Perren A. Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies.. [DOI: 10.1101/2022.12.10.519855] [Reference Citation Analysis]
3 Bremer SCB, Bittner G, Elakad O, Dinter H, Gaedcke J, König AO, Amanzada A, Ellenrieder V, Freiherr von Hammerstein-Equord A, Ströbel P, Bohnenberger H. Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis. Cancers (Basel) 2022;14:2828. [PMID: 35740494 DOI: 10.3390/cancers14122828] [Reference Citation Analysis]
4 Crabtree JS. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2022;12:901435. [DOI: 10.3389/fonc.2022.901435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sperling F, Misiak D, Hüttelmaier S, Michl P, Griesmann H. IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2. Cancers 2022;14:2121. [DOI: 10.3390/cancers14092121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sun S, Yu F, Xu D, Zheng H, Li M. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy. Biochim Biophys Acta Rev Cancer 2022;:188700. [PMID: 35217116 DOI: 10.1016/j.bbcan.2022.188700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]